IDCRC Newsletter: March 2024

IDCRC Profile: Noelle Myler, CCRA

Noelle Myler, CCRA, is a clinical research professional with more than 14 years of clinical trials experience within an academic research organization, a global clinical research organization, and a nonprofit human development organization. Noelle currently serves as a director of research within FHI 360’s Science Facilitation Department on the Infectious Diseases Clinical Research Consortium and the Sexual Transmitted Infections Clinical Trials Group, STI-CTG contract.

VIEW PROFILE

IDCRC congratulates, Dr. Kathy Neuzil, incoming Fogarty International Center Director and NIH Associate Director for International Research

The Infectious Diseases Clinical Research Consortium (IDCRC) Leadership Group and Vaccine & Treatment Evaluation Unit (VTEU) leadership congratulates Kathleen Neuzil, MD, who was announced as the incoming director of the Fogarty International Center and NIH associate director for international research.

Dr. Neuzil is the director of the Center for Vaccine Development and Global Health and chief of the Division of Geographic Medicine at the University of Maryland School of Medicine, Baltimore. She also serves as co-principal investigator of the IDCRC Leadership Group.

Please join us in congratulating Dr. Neuzil on her new role and expressing our thanks for her exemplary service and contributions to the IDCRC and infectious diseases prevention.

VIEW FULL ANNOUNCEMENT

Anthony Fauci, MD, joins IDCRC Mentoring and Training Key Function Committee for “Fireside Chat.”

On January 9, 2024, previous and current members of the IDCRC Leadership Group Mentoring and Career Development Committee (MCDC) had the distinct privilege of welcoming Anthony S. Fauci, MD, whose extraordinary career has included serving as the National Institute of Allergy and Infectious Diseases (NIAID) director from 1984 to 2022 and key advisor to seven U.S. presidents. Dr. Fauci joined this “fireside chat” as the guest speaker for the MCDC Mentoring Lecture Series. IDCRC junior investigators from the IDCRC Mentorship program had the unique opportunity to participate in an hour-long Q&A session with Dr. Fauci.

READ FULL STORY

Event

2024 IDCRC Annual Meeting

We look forward to meeting for the 2024 Annual Meeting this May! This year's robust program will highlight the numerous scientific accomplishments of the IDCRC and VTEUs and provide ample networking opportunities for members.

Date: May 1-2, 2024
Location: Hybrid: In-person and Virtual
5601 Fishers Lane,
Rockville, MD, 20892
Program of Events: View draft agenda

The Annual Meeting is limited to IDCRC, VTEU members, and our DMID partners. In-person attendance is offered by invitation only. Please e-mail idcrc@emory.edu if you would like to inquire about attendance.

Registration information is coming soon—please continue to check our website for updates.

Click below for further information on the meeting including the program, agenda, hotel options, and NIH Campus Access and Security.

ANNUAL MEETING WEBPAGE

Publications

NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

View recent publications below:

Congratulations Corner

Please join us in celebrating Dr. Kathy Neuzil's newest addition to her family—granddaughter, June Kathleen Neuzil, born on "Leap Day," February 29, 2024!

News

Mili Tapia receives 2024 Dean’s Faculty Award
for Diversity and Inclusion

Congratulations to Mili Tapia, MD, (University of Maryland) on her recent 2024 Dean’s Faculty Award for Diversity and Inclusion. She receives this recognition for her career achievements to enhance equity and diversity in research, notably her work in Mali and Maryland during the COVID-19 pandemic.

Zanthia Wiley, MD, FHM, FIDSA, named associate vice chair of DOM RYSE (DEI) for Emory University's Department of Medicine

Former IDCRC mentee, Zanthia Wiley, MD, FHM, FIDSA, was recently appointed as Emory University's Department of Medicine associate vice chair of Represent, Support, Elevate (RYSE), the department’s initiative in diversity, equity, and inclusion (DEI), effective April 1. Congratulations, Dr. Wiley!

READ FULL ANNOUNCEMENT

Training

Mentoring Lecture Series

Statistics in Developing a Proposal
Focus on Secondary/Exploratory Analyses

Presenter: Elizabeth Brown, ScD, IDCRC SDSU Director

VIDEO ARCHIVE

Job Postings

Infectious Diseases Research Job Openings

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

Funding Opportunities

NIH Funding Opportunities Specific to COVID-19
This page contains a listing of active and expired funding opportunities.

RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)
– Due Friday, April 5
The purpose of this FOA is to support the development and/or pre-clinical studies of non-viral technologies to deliver RNA-based therapeutics into disease-relevant cells and tissues in vivo.

Centers for Disease Control and Prevention (CDC): Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)
– Due Tuesday, April 30
The purpose of this FOA is to protect the public health and safety of the American people by enhancing the capacity of public health agencies to effectively detect, respond, prevent and control known an emerging (or re-emerging) infectious diseases.

Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)
– Due Tuesday, April 30
The Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Notice of Funding Opportunity (NOFO) builds upon the program that was initiated in 1995 as one of the key activities under CDC’s plan to address emerging infectious disease threats. The purpose of this NOFO is to protect the public health and safety of the American people by enhancing the capacity of public health agencies to effectively detect, respond, prevent and control known an emerging (or re-emerging) infectious diseases. This is accomplished by providing financial and technical resources to (1) strengthen epidemiologic capacity; (2) enhance laboratory capacity; (3) improve information systems; and (4) enhance collaboration among epidemiology, laboratory, and information systems components of public health departments.

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) – Due May 7, 2024; Due September 7, 2024
The purpose of this Notice of Funding Opportunity (NOFO) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) – Due June 8, 2024; 2025
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.

International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) – Due August 2, 2024; 2025
The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification).

NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) – Due 30 days prior (LOI); 10/11/2024; 10/10/2025 (Full app)
The NIAID New Innovator Award supports postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.

Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) – Due January 07, 2026
The purpose of this notice of funding opportunity (NOFO) is to invite applications from research institutions in low- and middle-income countries (LMICs) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in LMICs.

Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission – Due March 13, 2025; 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

Notice of Special Interest (NOSI): Complement in Fundamental Immunology – Due January 08, 2026
The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components. The work to be encouraged includes studies of the roles of complement components (molecules and/or receptors) during immune responses.

Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine –Due January 15, 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.

Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives – Due July 17, 2026
The purpose of this Notice of Special Interest (NOSI) is to invite applications for research on the use of targeted protein and nonprotein degradation (e.g., RNA) as it relates to the development of anti-infective strategies against viral, bacterial, parasitic, and fungal pathogens and/or their toxins (e.g., Lethal and Edema Toxins of Bacillus anthracis). Both novel monofunctional (e.g., Molecular Glues) and hetero-bi/tri-functional (e.g., PROTAC or PROTAC-like) strategies will be considered.

IDCRC Studies

Active Studies
Recruiting Volunteers

DMID Protocol 22-0019: A Phase 4 Study of a 3-Day vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection
Safety and Immunogenicity of CJCV2 With and Without ALFQ (DMID 19-0003)
Pharmacokinetic Study of IV Aresunate to Treat Children With Severe Malaria (DMID 19-0007)

Fully Enrolled Studies
in Follow-up

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine (DMID 20-0024)
Moderna’s mRNA-1273 vaccine, the KidCOVE Study (mRNA-1273-P204)